A review of the properties of a new specific 5-HT reuptake inhibitor — fluvoxamine maleate

  • Jennifer S Wakelin


Some years back the Clinical Research Department of Duphar B.V. was presented with a new non-tricyclic compound which, pharmacologically, was characterized as an antidepressant with few side-effects. We attempted to confirm this activity in the clinic.


Clinical Global Impression Unwanted Effect Salivary Flow Anticholinergic Effect Healthy Volunteer Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cella, S., Penalva, A., Locatelli, V., Novelli, A., Cocchi, D., and Muller, E. E. (1982). Neuroendocrine studies with fluvoxamine: animal data. Brit.J.Clin.Pharm., 15:357S–364SCrossRefGoogle Scholar
  2. Claassen, V. (1983). The animal pharmacology and pharmacokinetics of fluvoxamine. Brit.J.Clin.Pharm., 15:349S–364SCrossRefGoogle Scholar
  3. Claassen, V., Davies, J. E., Hertting, G. and Placheta, P. (1977). Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Brt.J.Pharm., 60:505–516CrossRefGoogle Scholar
  4. Coppen, A. (1972). Indoleamines and affective disorders. J.Psychiat.Res., 9:163–171PubMedCrossRefGoogle Scholar
  5. Davies, B. (1977). Problems of clinical research into affective disorders. In: G. Burrows (ed.), Handbook of Studies on Depression, Excerpta Medica, Amsterdam/London/New York, pp. 217–282Google Scholar
  6. De Wilde, J. E. M. and Doogan, D. P. (1982), Fluvoxamine and chlorimipramine in endogenous depression. J.Aff.Dis., 4:249–259CrossRefGoogle Scholar
  7. Dick, P. and Ferrero, E. (1983). A double-blind comparative study of clinical efficacy of fluvoxamine and clorimipramine. Brit.J.Clin.Pharm., 15:419S–425SCrossRefGoogle Scholar
  8. Feighner, J. P., Robinson, E., Quze, S. B., Woodruff, R. A., Winokur, G. and Munoz, R. (1972). Diagnostic criteria for use in psychiatric research. Arch.Gen.Psych., 26:56–73CrossRefGoogle Scholar
  9. Feldman, H. S. and Denber, H. O. B. (1982). Long term study of fluvoxamine: a new rapid acting antidepressant. Int.Pharmacopsych., 17:114–1221Google Scholar
  10. Guelfi, J. D., Dreyfus J. F., Pichot, P. and the G. E. P. E. C. E. P. (1983). A double-blind controlled trial comparing fluvoxamine with imipramine. Brit.J.Clin.Pharm., 15:411S–417SCrossRefGoogle Scholar
  11. Guy, W. (1976). In: ECDEU Assesment Manual, D.H.E.W. Publication no. 76–338, pp. 217–222Google Scholar
  12. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. Brit.J.Soc.CLin.Psychol., 6:278–296CrossRefGoogle Scholar
  13. Herberg, K. W. and Menke, H. (1981). Studies of the effect of the antidepressant fluvoxamine on driving ability and its alcohol interaction. Durphar Report No. H.114.5074, Duphar BV, The NetherlandsGoogle Scholar
  14. Itil, T. Bhattachyariya, A., Povan, N., Hugue, M. and Menon, G. N. (1977). Fluvoxamine (DU23000), a new antidepressant: Quantitative pharmaco-electro encepholography and pilot clinical trials. In: B. Saletu (ed.), Progress in Neuropsychopharmacology, vol. 1, Pergamon Press, Oxford/New York, pp. 309–322.Google Scholar
  15. Itil, T. M., Shrivastava, R. K., Makherjee, S., Coleman, B. and Michael, S. T. (1983). A double-blind placebo controlled study of fluvoxamine (DU23000) and imipramine in outpatients with primary depression. Brit.J.Clin.Pharm., 15:433S–438SCrossRefGoogle Scholar
  16. Kletzky, O. A., St. Michel, P., Mashchak, C. A. and Coleman, B. (1982). Acute effect of fluvoxamine, a new serotonin reuptake inhibitor, on hypothalamic-pituitary function. Eur.J. Clin.Pharm., (in press)Google Scholar
  17. Klok, C. J., Brouwer, H. M., Van Praag, H. M. and Doogan, D. (1981). Fluvoxamine and clomipramine in depressed patients, a double-blind clinical study. Acta Psychiat.Scand., 64: 1–11PubMedCrossRefGoogle Scholar
  18. Lapierre, Y. D., Oyewumi, L. K. and Coleman, B. (1981). The efficacy of fluvoxamine as an antidepressant. Clin.Trials J., 18:5, 313–320Google Scholar
  19. Lapin, I. P. and Oxenkrug, G. F. (1969). Intensification of the central scrotonergic properties as a possible determinant of the thymoleptic effect. Lancet, i: 132–136Google Scholar
  20. Marks J. (1965). In J. Marks and Ø C. M. B. Pare (eds.), The Scientific Basis of Drug Therapy in Psychiatry, Pergamon Press, New York, pp. 103–113Google Scholar
  21. Robinson, J. F. and Doogan, D. P. (1982). A placebo controlled cardiotoxicity study of antidepressant drugs, fluvoxamine and clovoxamine in human volunteers. Brit.J.Clin.Pharmac., 14:805–808CrossRefGoogle Scholar
  22. Robles de Medina, E. O. (1972). A New Coding System for Electrocardiography, Excerpta Medica, Amsterdam, pp.63–99Google Scholar
  23. Saletu, B. Grunberger, J. Ranja, P. and Karobath, M. (1980). Clovoxamine and fluvoxamine — 2 biogenic amine reuptake inhibiting antidepressants: Quantitative EEG, Psychometric and Pharmacokinetic studies in man. J.Neurol.Trans., 49: 63–68CrossRefGoogle Scholar
  24. Saletu, B., Schjerve, M., Grunberger, J. and Schanda, A. O. H. (1977). Fluvoxamine — a new serotonin reuptake inhibitor: first clinical and psychometric experiences in depressed patients. J.Neurol.Trans., 41:17–36CrossRefGoogle Scholar
  25. Spencer, P. S. J. (1977). Review of the pharmacology of existing antidepressants. Brit.J.Clin.Pharm., 4:575–685CrossRefGoogle Scholar
  26. Wilson, W. H., Ban, T. A., Higano, Y. and Kelwala, S. (1983). A double-blind placebo-controlled comparison of the autonomic effects of fluvoxamine and those of amitriptyline and doxepin in healthy volunteers. Brit.J.Clin.Pharm., 15:385S–392SCrossRefGoogle Scholar

Copyright information

© The contributors 1983

Authors and Affiliations

  • Jennifer S Wakelin
    • 1
  1. 1.Head Clinical Psychotropic Research Group, Clinical Research DepartmentDuphar B. V.WeespNetherlands

Personalised recommendations